These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Tjokroprawiro A Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268 [TBL] [Abstract][Full Text] [Related]
7. Assessment of metabolic profile in a clinical setting. Pervanidou P; Kanaka-Gantenbein C; Chrousos GP Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):589-95. PubMed ID: 16912555 [TBL] [Abstract][Full Text] [Related]
8. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Vega GL Endocrinol Metab Clin North Am; 2004 Sep; 33(3):525-44, vi. PubMed ID: 15262295 [TBL] [Abstract][Full Text] [Related]
9. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Nisoli E; Carruba MO Pharmacol Res; 2004 Nov; 50(5):453-69. PubMed ID: 15458765 [TBL] [Abstract][Full Text] [Related]
10. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk. Smith SR Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Ogawa Y; Kikuchi T; Nagasaki K; Hiura M; Tanaka Y; Uchiyama M Hypertens Res; 2005 Jan; 28(1):51-7. PubMed ID: 15969255 [TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome. Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517 [TBL] [Abstract][Full Text] [Related]
13. Protective role of pravastatin in the pathogenesis of the metabolic syndrome. Yamagishi S; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951 [TBL] [Abstract][Full Text] [Related]
14. The progression of cardiovascular risk to cardiovascular disease. Rosin BL Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392 [TBL] [Abstract][Full Text] [Related]
15. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Schindler C Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):7-26. PubMed ID: 19124392 [TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome: an evolving concept. Cortez-Dias N; Martins S; Fiuza M Rev Port Cardiol; 2007 Dec; 26(12):1409-21. PubMed ID: 18338669 [TBL] [Abstract][Full Text] [Related]
17. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Reilly MP; Wolfe ML; Rhodes T; Girman C; Mehta N; Rader DJ Circulation; 2004 Aug; 110(7):803-9. PubMed ID: 15289378 [TBL] [Abstract][Full Text] [Related]